<DOC>
	<DOCNO>NCT02426359</DOCNO>
	<brief_summary>This randomize , double-blind , vehicle-controlled , parallel-group comparison study evaluate safety efficacy Q301 Cream vs. vehicle adult subject moderate severe AD . Study drug ( Q301 Cream vehicle ) administer topically twice day 8 consecutive week .</brief_summary>
	<brief_title>Safety Efficacy Study Q301 Moderate Severe Atopic Dermatitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Male female subject age 18 old 2 . Subjects clinical diagnosis AD accord Hanifin Rajka Criteria board certified/eligible dermatologist 3 . Subjects IGA score 3 4 correspond moderate severe AD screening baseline visit 1 . Subjects topical treatment corticosteroid within 1 week randomization 2 . Subjects systemic treatment corticosteroid cyclosporine immunosuppressive treatment within 4 week randomization 3 . Subjects ultraviolet irradiation ( include photopheresis ) within 4 week screen 4 . Subjects participate another drug trial within 4 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>